IFN Lambda Deficiency Contributes to Severe COVID-19 Outcomes
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910530 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Anna Zaleska und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergology and Internal Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health subvention.
Abstract (Originalsprache)
Interferons (IFNs) produced by airway epithelial cells are crucial in defending against pathogens. Fluctuations in IFN-λ levels may influence coronavirus disease 19 (COVID-19) severity. However, conflicting data have been reported regarding serum IFN-λ concentrations in COVID-19 patients. To address this, we evaluated serum IFN-λ levels over time in moderate and severe COVID-19 patients and their association with cytokine production and clinical parameters using the enzyme-linked immunosorbent assay (ELISA) and the Bio-Plex Pro Human Cytokine 17-plex Assay. Results from testing 51 COVID-19 patients showed that 68% lacked detectable serum IFN-λ. Among non-IFN-λ secretors, severe COVID-19 predominated. In contrast, IFN-λ secretors displayed stable IFN-λ levels in moderate cases, while severe cases showed a decline over time, which persisted even after recovery. A negative correlation was observed between IFN-λ levels and inflammatory markers. This, combined with an increase in tumor necrosis factor alpha (TNF-α) and clinical improvement, suggests a regulatory role for IFN-λ in promoting faster recovery. Despite this, survival rates were similar between the groups, indicating that while IFN-λ influences the course of the disease, it does not directly affect overall survival. In conclusion, IFN-λ is vital, but not unique, for the antiviral response and COVID-19 recovery. Simultaneously, serum IFN-λ deficiency signifies severe COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergology and Internal Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland.
- Department of Social Sciences and Infectious Diseases, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.
- Department of Infectious Diseases and Hepatology, Wroclaw Medical University, 50-367 Wroclaw, Poland.
- Department of Immunology and Allergy, Medical University of Lodz, 92-213 Lodz, Poland.
ORCID-Profile: Anna Zaleska, Anna Dor-Wojnarowska, Marta Rorat, Wojciech Szymański, Adrian Gajewski, Maciej Chałubiński
Förderung
- Ministry of Health subvention
Zitieren
APA
Zaleska, A., Dor-Wojnarowska, A., Radlińska, A., Rorat, M., Szymański, W., Gajewski, A., & Chałubiński, M. (2024). IFN Lambda Deficiency Contributes to Severe COVID-19 Outcomes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910530
Vancouver
Zaleska A, Dor-Wojnarowska A, Radlińska A, Rorat M, Szymański W, Gajewski A, et al. IFN Lambda Deficiency Contributes to Severe COVID-19 Outcomes. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910530
BibTeX
@article{Zaleska2024,
author = {Zaleska, Anna and Dor-Wojnarowska, Anna and Radlińska, Anna and Rorat, Marta and Szymański, Wojciech and Gajewski, Adrian and Chałubiński, Maciej},
title = {IFN Lambda Deficiency Contributes to Severe COVID-19 Outcomes},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910530}
}
EUVIMED